Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 1

Status

Completed 3

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Hyperuricemia 8Lymphoma 4Leukemia 4Tumor Lysis Syndrome 3Neoplasms 2Recurrence 1Nutritional and Metabolic Diseases 1Myelodysplastic Syndromes 1

Interventions

rasburicase 3Urate Oxidase 3Febuxostat 2Allopurinol 2venetoclax 1obinutuzumab 1Lenalidomide 1Bendamustine Hydrochloride 1AZD0466 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Tumor Lysis Syndrome × rasburicase × Clear all
NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

NCT00230217 2009-03-30

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Sanofi

Phase 4 Completed
94 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms, Recurrence, Tumor Lysis Syndrome, Hyperuricemia

NCT00651911 2008-04-03

Fasturtec TLS Treatment / Prophylysis

Sanofi

Phase 4 Completed
45 enrolled

Tumor Lysis Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡